ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery and development, announces ...
Pipeline
ImmuPharma is a biopharmaceutical company that specialises in the usage and development of biopolymers, specifically peptides.
Our late-stage to preclinical pipeline is focused on two core therapeutic areas; autoimmunity & inflammation and anti-infectives.


*Phase 2/3 adaptive trial becomes a pivotal trial for filing

Our core therapeutic areas
The P140 platform
LUPUZORTM for Lupus
P140 for CIDP
BioAMB
for systemic fungal infections
BioCIN
for severe bacterial infections
Key progress
Lanstead Subscription & Oversubscribed Placing to ‘c.£2.91 million | Sharing Agreement | Related Party Transactions
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased ...
ImmuPharma Announces Breakthrough Findings into Autoimmune Diseases
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements ...